GlaxoSmithKline (GSK) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
BofA/Merrill Lynch Downgrades GlaxoSmithKline (GSK) to Neutral
October 26, 2017 4:42 AM EDTBofA/Merrill Lynch downgraded GlaxoSmithKline (NYSE: GSK) from Buy to Neutral.
Analyst Graham Parry says the valuation is not demanding and sees growing uncertainties likely capping P/E recovery into 2018 stemming from margin pressure and consensus EPS reductions on Advair generics... More
